Jieun Han
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Jieun Han has a total of 45 co-authors. Here are the top co-authors by number of shared publications:
- Wooram Park
Department of Integrative Biotechnology, College of Biotechnology and Bioengineering, Sungkyunkwan University (SKKU), Suwon, Republic of Korea
6 shared publications - Chun Gwon Park
Department of Intelligent Precision Healthcare Convergence, Institute for Cross-disciplinary Studies (ICS), Sungkyunkwan University (SKKU), Suwon, Gyeonggi 16419, Republic of Korea; Department of Biomedical Engineering, ICS, SKKU, Suwon, Gyeonggi 16419, Republic of Korea
3 shared publications - Dong-Hyun Kim
Department of Radiology, Feinberg School of Medicine, Northwestern University, Chicago, USA
3 shared publications - Ga‐Hyun Bae
Department of MetaBioHealth Institute for Cross‐disciplinary Studies (ICS) Sungkyunkwan University (SKKU) Seobu‐ro 2066 Suwon Gyeonggi 16419 Republic of Korea
3 shared publications - Jun‐Hyeok Han
Department of Radiology Northwestern University Chicago Illinois USA
3 shared publications - Eun‐Young Koh
Department of MetaBioHealth Institute for Cross‐disciplinary Studies (ICS) Sungkyunkwan University (SKKU) Seobu‐ro 2066 Suwon Gyeonggi 16419 Republic of Korea
2 shared publications
Latest Publications
- Open Access
- 12 November 2025
- Published by Wiley in Advanced Healthcare Materials
- Vol. 15 (7) , e03748
Photosensitizing Lipid Nanoparticles for Ferroptosis‐Enhanced Photodynamic Cancer Therapy via GPX4 Silencing
Ferroptosis, a regulated form of non‐apoptotic cell death driven by iron‐dependent lipid peroxidation, has emerged as a promising approach for overcoming therapy‐resistant cancers. A multifunctional lipid nanoparticle (LNP) platform was developed to integrate ferroptosis induction with photodynamic therapy (PDT) for synergistic anticancer effects. By partially substituting cholesterol in conventional DLin‐MC3‐DMA (MC3)‐based LNPs with cholesterol—polyethylene glycol (PEG)–pheophorbide a (CPP), we engineered photosensitizing lipid nanoparticles (PLNPs) capable of delivering glutathione peroxidase 4 (GPX4)‐targeting small interfering RNA (siRNA). Upon laser irradiation, the PLNPs generate reactive oxygen species (ROS) through PDT, while siRNA‐mediated GPX4 silencing promotes ferroptosis by disrupting cellular antioxidant defenses. The PLNPs demonstrate favorable physicochemical characteristics, efficient gene silencing, and potent ROS production. In vitro experiments in 4T1 and EO771 breast cancer cells reveal enhanced cytotoxicity under combined treatment, underscoring the synergistic interaction between PDT‐induced oxidative stress and ferroptotic cell death. In vivo, the PLNPs exhibit prolonged tumor retention, effective GPX4 knockdown, and significant tumor growth inhibition, with minimal systemic toxicity. Overall, this work introduces a dual‐function nanoplatform that potentiates photodynamic cancer therapy through ferroptosis induction and offers a versatile strategy for developing next‐generation combination treatments targeting aggressive tumors.
- 12 November 2025
- Published by Wiley in Advanced Healthcare Materials
- Vol. 15 (7) , e03748
Open AccessPhotosensitizing Lipid Nanoparticles for Ferroptosis‐Enhanced Photodynamic Cancer Therapy via GPX4 Silencing
Ferroptosis, a regulated form of non‐apoptotic cell death driven by iron‐dependent lipid peroxidation, has emerged as a promising approach for overcoming therapy‐resistant cancers. A multifunctional lipid nanoparticle (LNP) platform was developed to integrate ferroptosis induction with photodynamic therapy (PDT) for synergistic anticancer effects. By partially substituting cholesterol in conventional DLin‐MC3‐DMA (MC3)‐based LNPs with cholesterol—polyethylene glycol (PEG)–pheophorbide a (CPP), we engineered photosensitizing lipid nanoparticles (PLNPs) capable of delivering glutathione peroxidase 4 (GPX4)‐targeting small interfering RNA (siRNA). Upon laser irradiation, the PLNPs generate reactive oxygen species (ROS) through PDT, while siRNA‐mediated GPX4 silencing promotes ferroptosis by disrupting cellular antioxidant defenses. The PLNPs demonstrate favorable physicochemical characteristics, efficient gene silencing, and potent ROS production. In vitro experiments in 4T1 and EO771 breast cancer cells reveal enhanced cytotoxicity under combined treatment, underscoring the synergistic interaction between PDT‐induced oxidative stress and ferroptotic cell death. In vivo, the PLNPs exhibit prolonged tumor retention, effective GPX4 knockdown, and significant tumor growth inhibition, with minimal systemic toxicity. Overall, this work introduces a dual‐function nanoplatform that potentiates photodynamic cancer therapy through ferroptosis induction and offers a versatile strategy for developing next‐generation combination treatments targeting aggressive tumors.
- Open Access
- 3 March 2025
- Published by Wiley in Advanced Healthcare Materials
- Vol. 14 (15) , e2404819
Dual‐Functional Hafnium Oxide Nanoplatform Combining High‐Z Radiosensitization With Bcl‐2 Gene Silencing for Enhanced Cancer Radiotherapy
The efficacy of radiotherapy is often limited by insufficient radiosensitization and tumor radioresistance. This study reports a dual‐functional hafnium oxide nanoplatform that combines high‐Z radiosensitization with Bcl‐2 gene silencing for enhanced cancer radiotherapy. The nanoplatform is developed by surface modification of hafnium oxide nanoparticles with polyethyleneimine, enabling efficient siRNA delivery while maintaining inherent high‐Z radiosensitizing properties. Comprehensive physicochemical characterization confirmed the successful surface modification and stable siRNA complexation. Upon radiation exposure, the nanoplatform enhanced reactive oxygen species generation and DNA damage while simultaneously delivering Bcl‐2 siRNA to suppress radioresistance mechanisms. In vitro studies revealed significant enhancement of radiation‐induced cell death through synergistic effects of high‐Z radiosensitization and Bcl‐2 silencing, evidenced by increased γ‐H2AX expression and apoptotic cell population. In a murine colon cancer model, the nanoplatform achieved remarkable tumor growth inhibition (80%) when combined with radiotherapy while exhibiting favorable biocompatibility in major organs. Mechanistic studies confirmed effective Bcl‐2 downregulation and enhanced DNA damage in tumor tissues, validating this dual‐functional therapeutic approach. This study presents a promising strategy for improving radiotherapy outcomes through the simultaneous enhancement of radiosensitization and suppression of radioresistance, potentially advancing the field of cancer radiotherapy.
- 3 March 2025
- Published by Wiley in Advanced Healthcare Materials
- Vol. 14 (15) , e2404819
Open AccessDual‐Functional Hafnium Oxide Nanoplatform Combining High‐Z Radiosensitization With Bcl‐2 Gene Silencing for Enhanced Cancer Radiotherapy
The efficacy of radiotherapy is often limited by insufficient radiosensitization and tumor radioresistance. This study reports a dual‐functional hafnium oxide nanoplatform that combines high‐Z radiosensitization with Bcl‐2 gene silencing for enhanced cancer radiotherapy. The nanoplatform is developed by surface modification of hafnium oxide nanoparticles with polyethyleneimine, enabling efficient siRNA delivery while maintaining inherent high‐Z radiosensitizing properties. Comprehensive physicochemical characterization confirmed the successful surface modification and stable siRNA complexation. Upon radiation exposure, the nanoplatform enhanced reactive oxygen species generation and DNA damage while simultaneously delivering Bcl‐2 siRNA to suppress radioresistance mechanisms. In vitro studies revealed significant enhancement of radiation‐induced cell death through synergistic effects of high‐Z radiosensitization and Bcl‐2 silencing, evidenced by increased γ‐H2AX expression and apoptotic cell population. In a murine colon cancer model, the nanoplatform achieved remarkable tumor growth inhibition (80%) when combined with radiotherapy while exhibiting favorable biocompatibility in major organs. Mechanistic studies confirmed effective Bcl‐2 downregulation and enhanced DNA damage in tumor tissues, validating this dual‐functional therapeutic approach. This study presents a promising strategy for improving radiotherapy outcomes through the simultaneous enhancement of radiosensitization and suppression of radioresistance, potentially advancing the field of cancer radiotherapy.
- 31 December 2024
- Published by Wiley in Advanced Functional Materials
- Vol. 35 (25)
Engineered Cell‐Derived Nanovesicles with CAR and PH20 for Enhanced Targeted Photodynamic Cancer Therapy and Tumor Microenvironment Modulation
Photodynamic therapy (PDT) is a promising cancer treatment, but its clinical use is limited by nontargeted photosensitizers (PS) that accumulate in normal tissues, causing adverse effects, and poor penetration in tumor tissues due to the dense extracellular matrix (ECM). Here an innovative approach is presented using cell‐derived nanovesicles (CNVs) engineered with chimeric antigen receptor (CAR) and hyaluronidase PH20 to enhance targeted PDT. The CAR–PH20 CNVs, loaded with the photosensitizer pheophorbide a (PheoA), specifically target HER2‐expressing tumor cells and degrade hyaluronic acid in the tumor microenvironment (TME), improving tumor penetration and drug distribution. In vitro and in vivo experiments demonstrate increased reactive oxygen species (ROS) generation, improved tumor retention, and enhanced therapeutic efficacy compared to conventional methods. When combined with laser irradiation, these CNVs induce significant tumor cell apoptosis and inhibit tumor growth in mouse models, while minimizing toxicity to normal tissues. This platform offers a promising strategy for targeted, TME‐modulating PDT with improved efficacy, and reduced side effects, marking a significant advance in nanodrug‐based cancer therapies.
- 31 December 2024
- Published by Wiley in Advanced Functional Materials
- Vol. 35 (25)
Engineered Cell‐Derived Nanovesicles with CAR and PH20 for Enhanced Targeted Photodynamic Cancer Therapy and Tumor Microenvironment Modulation
Photodynamic therapy (PDT) is a promising cancer treatment, but its clinical use is limited by nontargeted photosensitizers (PS) that accumulate in normal tissues, causing adverse effects, and poor penetration in tumor tissues due to the dense extracellular matrix (ECM). Here an innovative approach is presented using cell‐derived nanovesicles (CNVs) engineered with chimeric antigen receptor (CAR) and hyaluronidase PH20 to enhance targeted PDT. The CAR–PH20 CNVs, loaded with the photosensitizer pheophorbide a (PheoA), specifically target HER2‐expressing tumor cells and degrade hyaluronic acid in the tumor microenvironment (TME), improving tumor penetration and drug distribution. In vitro and in vivo experiments demonstrate increased reactive oxygen species (ROS) generation, improved tumor retention, and enhanced therapeutic efficacy compared to conventional methods. When combined with laser irradiation, these CNVs induce significant tumor cell apoptosis and inhibit tumor growth in mouse models, while minimizing toxicity to normal tissues. This platform offers a promising strategy for targeted, TME‐modulating PDT with improved efficacy, and reduced side effects, marking a significant advance in nanodrug‐based cancer therapies.
- 28 February 2024
- Published by American Chemical Society (ACS) in ACS Applied Materials & Interfaces
- Vol. 16 (10) , 13139-13149
Magnetically Actuated Trigger Transient Soft Actuators Comprising On-Demand Photo-Initiated and Thermo-Degradable Polypropylene Carbonate–Photo-Acid Generator
Lifetime-reconfigurable soft robots have emerged as a new class of robots, emphasizing the unmet needs of futuristic sustainability and security. Trigger-transient materials that can both actuate and degrade on-demand are crucial for achieving life-reconfigurable soft robots. Here, we propose the use of transient and magnetically actuating materials that can decompose under ultraviolet light and heat, achieved by adding photo-acid generator (PAG) and magnetic particles (Sr-ferrite) to poly(propylene carbonate) (PPC). Chemical and thermal analyses reveal that the mechanism of PPC-PAG decomposition occurs through PPC backbone cleavage by the photo-induced acid. The self-assembled monolayer (SAM) encapsulation of Sr-ferrite preventing the interaction with the PAG allowed the transience of magnetic soft actuators. We demonstrate remotely controllable and degradable magnetic soft kirigami actuators using blocks with various magnetized directions. This study proposes novel approaches for fabricating lifetime-configurable magnetic soft actuators applicable to diverse environments and applications, such as enclosed/sealed spaces and security/military devices.
- 28 February 2024
- Published by American Chemical Society (ACS) in ACS Applied Materials & Interfaces
- Vol. 16 (10) , 13139-13149
Magnetically Actuated Trigger Transient Soft Actuators Comprising On-Demand Photo-Initiated and Thermo-Degradable Polypropylene Carbonate–Photo-Acid Generator
Lifetime-reconfigurable soft robots have emerged as a new class of robots, emphasizing the unmet needs of futuristic sustainability and security. Trigger-transient materials that can both actuate and degrade on-demand are crucial for achieving life-reconfigurable soft robots. Here, we propose the use of transient and magnetically actuating materials that can decompose under ultraviolet light and heat, achieved by adding photo-acid generator (PAG) and magnetic particles (Sr-ferrite) to poly(propylene carbonate) (PPC). Chemical and thermal analyses reveal that the mechanism of PPC-PAG decomposition occurs through PPC backbone cleavage by the photo-induced acid. The self-assembled monolayer (SAM) encapsulation of Sr-ferrite preventing the interaction with the PAG allowed the transience of magnetic soft actuators. We demonstrate remotely controllable and degradable magnetic soft kirigami actuators using blocks with various magnetized directions. This study proposes novel approaches for fabricating lifetime-configurable magnetic soft actuators applicable to diverse environments and applications, such as enclosed/sealed spaces and security/military devices.
- Open Access
- 1 January 2024
- Published by American Association for the Advancement of Science (AAAS) in Biomaterials Research
- Vol. 28, 0008
Enhanced Postsurgical Cancer Treatment Using Methacrylated Glycol Chitosan Hydrogel for Sustained DNA/Doxorubicin Delivery and Immunotherapy
Background: Cancer recurrence and metastasis are major contributors to treatment failure following tumor resection surgery. We developed a novel implantable drug delivery system utilizing glycol chitosan to address these issues. Glycol chitosan is a natural adjuvant, inducing dendritic cell activation to promote T helper 1 cell immune responses, macrophage activation, and cytokine production. Effective antigen production by dendritic cells initiates T-cell-mediated immune responses, aiding tumor growth control. Methods: In this study, we fabricated multifunctional methacrylated glycol chitosan (MGC) hydrogels with extended release of DNA/doxorubicin (DOX) complex for cancer immunotherapy. We constructed the resection model of breast cancer to verify the anticancer effects of MGC hydrogel with DNA/DOX complex. Results: This study demonstrated the potential of MGC hydrogel with extended release of DNA/DOX complex for local and efficient cancer therapy. The MGC hydrogel was implanted directly into the surgical site after tumor resection, activating tumor-related immune cells both locally and over a prolonged period of time through immune-reactive molecules. Conclusions: The MGC hydrogel effectively suppressed tumor recurrence and metastasis while enhancing immunotherapeutic efficacy and minimizing side effects. This biomaterial-based drug delivery system, combined with cancer immunotherapy, can substantial improve treatment outcomes and patient prognosis.
- 1 January 2024
- Published by American Association for the Advancement of Science (AAAS) in Biomaterials Research
- Vol. 28, 0008
Open AccessEnhanced Postsurgical Cancer Treatment Using Methacrylated Glycol Chitosan Hydrogel for Sustained DNA/Doxorubicin Delivery and Immunotherapy
Background: Cancer recurrence and metastasis are major contributors to treatment failure following tumor resection surgery. We developed a novel implantable drug delivery system utilizing glycol chitosan to address these issues. Glycol chitosan is a natural adjuvant, inducing dendritic cell activation to promote T helper 1 cell immune responses, macrophage activation, and cytokine production. Effective antigen production by dendritic cells initiates T-cell-mediated immune responses, aiding tumor growth control. Methods: In this study, we fabricated multifunctional methacrylated glycol chitosan (MGC) hydrogels with extended release of DNA/doxorubicin (DOX) complex for cancer immunotherapy. We constructed the resection model of breast cancer to verify the anticancer effects of MGC hydrogel with DNA/DOX complex. Results: This study demonstrated the potential of MGC hydrogel with extended release of DNA/DOX complex for local and efficient cancer therapy. The MGC hydrogel was implanted directly into the surgical site after tumor resection, activating tumor-related immune cells both locally and over a prolonged period of time through immune-reactive molecules. Conclusions: The MGC hydrogel effectively suppressed tumor recurrence and metastasis while enhancing immunotherapeutic efficacy and minimizing side effects. This biomaterial-based drug delivery system, combined with cancer immunotherapy, can substantial improve treatment outcomes and patient prognosis.
- 1 November 2017
- Published by Royal Society of Chemistry (RSC) in Biomaterials Science
- Vol. 6 (1) , 79-90
Advanced smart-photosensitizers for more effective cancer treatment
Smart photosensitizers (PSs), combined with advanced nano- and biomaterial technology, have a great potential for efficient cancer treatment.
- 1 November 2017
- Published by Royal Society of Chemistry (RSC) in Biomaterials Science
- Vol. 6 (1) , 79-90
Advanced smart-photosensitizers for more effective cancer treatment
Smart photosensitizers (PSs), combined with advanced nano- and biomaterial technology, have a great potential for efficient cancer treatment.
- 21 March 2016
- Published by American Chemical Society (ACS) in ACS Applied Materials & Interfaces
- Vol. 8 (12) , 7739-7747
Photosensitizer-Conjugated Hyaluronic Acid-Shielded Polydopamine Nanoparticles for Targeted Photomediated Tumor Therapy
Photodynamic therapy (PDT) is a widely used clinical option for tumor therapy. However, the clinical utilization of conventional small-molecule photosensitizers (PSs) for PDT has been limited by their low selectivity for disease sites, and undesirable photo-activation. To overcome these limitations, we demonstrated a tumor-specific and photo-activity-controllable nanoparticle photomedicine based on a combination of PS-biomacromolecule conjugates and polydopamine nanoparticles (PD-NP) for an effective tumor therapy. This novel photomedicine consisted of a PD-NP core shielded with a PS-conjugated hyaluronic acid (PS-HA) shell. The PD-NP and the PS-HA play roles as a quencher for PSs and a cancer targeting moiety, respectively. The synthesized PS-HA-shielded PD-NPs (PHPD-NPs) had a relatively narrow size distribution (approximately 130 nm) with uniform spherical shapes. In response to cancer-specific intracellular enzymes (e.g., hyaluronidase), the PHPD-NPs exhibited an excellent singlet oxygen generation capacity for PDT. Furthermore, an efficient photothermal conversion ability for photothermal therapy (PTT) was also shown in the PHPD-NPs system. These properties provide superior therapeutic efficacy against cancer cells. In mice tumor model, the photoactive restorative effects of the PD-NPs were much higher in cancer microenvironments compared to that in the normal tissue. As a result, the PD-NPs showed a significant antitumor activity in in vivo mice tumor model. The nanoparticle photomedicine design is a novel strategy for effective tumor therapy.
- 21 March 2016
- Published by American Chemical Society (ACS) in ACS Applied Materials & Interfaces
- Vol. 8 (12) , 7739-7747
Photosensitizer-Conjugated Hyaluronic Acid-Shielded Polydopamine Nanoparticles for Targeted Photomediated Tumor Therapy
Photodynamic therapy (PDT) is a widely used clinical option for tumor therapy. However, the clinical utilization of conventional small-molecule photosensitizers (PSs) for PDT has been limited by their low selectivity for disease sites, and undesirable photo-activation. To overcome these limitations, we demonstrated a tumor-specific and photo-activity-controllable nanoparticle photomedicine based on a combination of PS-biomacromolecule conjugates and polydopamine nanoparticles (PD-NP) for an effective tumor therapy. This novel photomedicine consisted of a PD-NP core shielded with a PS-conjugated hyaluronic acid (PS-HA) shell. The PD-NP and the PS-HA play roles as a quencher for PSs and a cancer targeting moiety, respectively. The synthesized PS-HA-shielded PD-NPs (PHPD-NPs) had a relatively narrow size distribution (approximately 130 nm) with uniform spherical shapes. In response to cancer-specific intracellular enzymes (e.g., hyaluronidase), the PHPD-NPs exhibited an excellent singlet oxygen generation capacity for PDT. Furthermore, an efficient photothermal conversion ability for photothermal therapy (PTT) was also shown in the PHPD-NPs system. These properties provide superior therapeutic efficacy against cancer cells. In mice tumor model, the photoactive restorative effects of the PD-NPs were much higher in cancer microenvironments compared to that in the normal tissue. As a result, the PD-NPs showed a significant antitumor activity in in vivo mice tumor model. The nanoparticle photomedicine design is a novel strategy for effective tumor therapy.